Clinical trials: Edematous Fibrosclerotic Panniculopathy
Cellulite
Study Aimed at Evaluation of the Effectiveness and Tolerability of an Anti-cellulite Cream Medical Device
Post-marketing clinical study conducted on a CE medical device, named Defense Body, cellulite treatment, edematous fibrosclerotic panniculopathy (2nd and 3rd stage pathology), reducing draining cream-gel, to verify its…
- Trial name
- DEFBODY (NCT06348615)
- Testing
- Anti-cellulite cream-gel Medical Device (DEFBODY)
- Where
- Italy
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- ICIM International S.r.l.
Edematous Fibrosclerotic Panniculopathy, Cellulite
CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques
This study is designed to investigate the safety and efficacy of collagenase clostridium histolyticum (CCH) for the treatment of mild to moderate edematous fibrosclerotic panniculopathy (cellulite) in participants with moderate…
- Conditions
- Edematous Fibrosclerotic Panniculopathy, Cellulite, Laxity; Skin
- Trial name
- NCT04580303
- Testing
- collagenase clostridium histolyticum
- Where
- 3 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Edematous Fibrosclerotic Panniculopathy (Cellulite)
Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women
Subjects will be screened for study eligibility within 14 days prior to enrolling in this study. Subjects with 2 treatment areas (bilateral buttocks) with moderate or severe levels of cellulite as independently assessed by the…
- Trial name
- RELEASE-1 (NCT03428750)
- Testing
- EN3835
- Where
- 26 sites in United States
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Edematous Fibrosclerotic Panniculopathy
Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP
This study will evaluate the safety and Pharmacokinetics (PK) of a single 3.36-mg dose of Collagenase Clostridium Histolyticum (CCH) in 4 quadrants concurrently, in subjects with Edematous fibrosclerotic panniculopathy (EFP).
- Trial name
- NCT03675685
- Testing
- CCH (collagenase clostridium histolyticum)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Edematous Fibrosclerotic Panniculopathy (Cellulite)
Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women
Subjects will be screened for study eligibility within 14 days prior to enrolling in this study. Subjects with 2 treatment areas (bilateral buttocks) with moderate or severe levels of cellulite as independently assessed by the…
- Trial name
- RELEASE-2 (NCT03446781)
- Testing
- EN3835
- Where
- 25 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Edematous Fibrosclerotic Panniculopathy, Cellulite
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
The study will evaluate the safety, effectiveness, and immunogenicity of EN3835 in the treatment of adult women with Edematous Fibrosclerotic Panniculopathy (Commonly known as Cellulite).
- Trial name
- NCT02724644
- Testing
- COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
- Where
- 16 sites in United States
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Cellulite, Edematous Fibrosclerotic Panniculopathy (EFP)
Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women
This is a single center, open-label, Phase 2a study to assess the photonumeric scale, morphological, and histopathological changes associated with Collagenase Clostridium Histolyticum (CCH) in adult women with moderate or severe…
- Trial name
- NCT04209530
- Testing
- EN3835
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Edematous Fibrosclerotic Panniculopathy (EFP), Cellulite
Real World CCH Study in Adult Females With Cellulite
This is a multicenter, open-label, multiple dose, 2 cohort, Phase 3b study to assess the safety and efficacy of CCH in adult women with mild or moderate edematous fibrosclerotic panniculopathy (EFP).
- Trial name
- NCT04170296
- Testing
- EN3835
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Edematous Fibrosclerotic Panniculopathy (EFP), Cellulite
Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite
This study will investigate treatments that may mitigate bruising after QWO™ (Collagenase clostridium histolyticum [CCH]-aaes) treatment of cellulite in the buttocks.
- Trial name
- MOBI (NCT04677712)
- Testing
- CCH-aaes, Compression, Cold Packs
- Where
- 8 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Edematous Skin
Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)
The study will evaluate the safety and effectiveness of different injection techniques of Collagenase Clostridium Histolyticum (CCH) for the treatment of adult women with mild, moderate or severe Edematous Fibrosclerotic…
- Trial name
- NCT03632993
- Testing
- collagenase clostridium histolyticum (CCH)
- Where
- 5 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company